{"hands_on_practices": [{"introduction": "The journey of a signal begins at the cell surface, where ligands bind to receptors. This initial step is often a competition, a molecular \"battle\" between different molecules for the same binding site. This practice explores the quantitative nature of this interaction, focusing on how a therapeutic agonist must compete with a naturally occurring antagonist [@problem_id:2315143]. By applying the concept of the dissociation constant ($K_d$), you will calculate the drug concentration needed to achieve a desired level of receptor activation, a fundamental skill in pharmacology and drug design.", "problem": "A team of pharmacologists is studying a newly synthesized drug, \"Synthogen,\" which acts as an agonist for a specific G-protein coupled receptor known as the Proliferation Factor Receptor (PFR). Activation of PFR by an agonist is known to trigger a cell proliferation signaling cascade. The team discovers that a naturally occurring metabolite, \"Inhibitin,\" is present in the cellular environment and acts as a competitive antagonist by binding to the same site on PFR without activating it.\n\nThe binding dynamics are characterized by the dissociation constants ($K_d$), where $K_d$ is the concentration of a ligand at which half of the receptors are occupied by that ligand in the absence of any competing ligands. The dissociation constant for Synthogen binding to PFR is $K_S = 50.0$ nM, and for Inhibitin binding to PFR is $K_I = 100.0$ nM. Assume the physiological concentration of Inhibitin is constant at $[I] = 200.0$ nM.\n\nThe magnitude of the cellular response is directly proportional to the fraction of PFRs bound by the agonist, Synthogen. To achieve a therapeutically effective outcome, 50% of the total PFR population must be bound by Synthogen.\n\nCalculate the concentration of Synthogen required to achieve this target. Express your answer in units of nanomolars (nM), rounded to three significant figures.", "solution": "The problem asks for the concentration of an agonist (Synthogen, S) required to achieve 50% receptor occupancy in the presence of a competitive antagonist (Inhibitin, I).\n\nLet $[R_{total}]$ be the total concentration of the Proliferation Factor Receptor (PFR). This total concentration is distributed among three states: free receptors $[R]$, receptors bound to Synthogen $[RS]$, and receptors bound to Inhibitin $[RI]$. The conservation of receptors can be expressed as:\n$$[R_{total}] = [R] + [RS] + [RI]$$\n\nThe binding of Synthogen and Inhibitin to the receptor are equilibrium processes, described by their respective dissociation constants, $K_S$ and $K_I$:\nFor Synthogen (S): $S + R \\rightleftharpoons RS$\n$$K_S = \\frac{[S][R]}{[RS]}$$\nFor Inhibitin (I): $I + R \\rightleftharpoons RI$\n$$K_I = \\frac{[I][R]}{[RI]}$$\n\nWe can rearrange these equilibrium equations to express the concentrations of the bound complexes in terms of the free receptor concentration $[R]$:\n$$[RS] = \\frac{[S][R]}{K_S}$$\n$$[RI] = \\frac{[I][R]}{K_I}$$\n\nThe goal is to find the concentration of Synthogen, $[S]$, such that the fraction of receptors bound by Synthogen is 0.50. This fraction, which we can call $\\theta_S$, is defined as:\n$$\\theta_S = \\frac{[RS]}{[R_{total}]}$$\n\nSubstitute the expression for $[R_{total}]$ into the denominator:\n$$\\theta_S = \\frac{[RS]}{[R] + [RS] + [RI]}$$\n\nNow, substitute the expressions for $[RS]$ and $[RI]$ from the rearranged equilibrium equations into this fractional occupancy equation:\n$$\\theta_S = \\frac{\\frac{[S][R]}{K_S}}{[R] + \\frac{[S][R]}{K_S} + \\frac{[I][R]}{K_I}}$$\n\nThe concentration of free receptor, $[R]$, appears in every term in the numerator and denominator, so it can be canceled out. This simplifies the expression, making it independent of the total receptor concentration:\n$$\\theta_S = \\frac{\\frac{[S]}{K_S}}{1 + \\frac{[S]}{K_S} + \\frac{[I]}{K_I}}$$\n\nWe are given the target condition $\\theta_S = 0.50$. We can now solve for $[S]$:\n$$0.50 = \\frac{\\frac{[S]}{K_S}}{1 + \\frac{[S]}{K_S} + \\frac{[I]}{K_I}}$$\n\nTo solve for $[S]$, we rearrange the equation algebraically:\n$$0.50 \\left( 1 + \\frac{[S]}{K_S} + \\frac{[I]}{K_I} \\right) = \\frac{[S]}{K_S}$$\n$$0.50 + 0.50 \\frac{[S]}{K_S} + 0.50 \\frac{[I]}{K_I} = \\frac{[S]}{K_S}$$\n\nNext, we group the terms containing $[S]$ on one side of the equation:\n$$0.50 + 0.50 \\frac{[I]}{K_I} = \\frac{[S]}{K_S} - 0.50 \\frac{[S]}{K_S}$$\n$$0.50 \\left( 1 + \\frac{[I]}{K_I} \\right) = 0.50 \\left( \\frac{[S]}{K_S} \\right)$$\nThe factor of $0.50$ cancels from both sides:\n$$1 + \\frac{[I]}{K_I} = \\frac{[S]}{K_S}$$\n\nFinally, we isolate $[S]$ to get the symbolic expression for the required Synthogen concentration:\n$$[S] = K_S \\left( 1 + \\frac{[I]}{K_I} \\right)$$\n\nNow we can substitute the given numerical values: $K_S = 50.0$ nM, $K_I = 100.0$ nM, and $[I] = 200.0$ nM.\n$$[S] = 50.0 \\, \\text{nM} \\left( 1 + \\frac{200.0 \\, \\text{nM}}{100.0 \\, \\text{nM}} \\right)$$\n$$[S] = 50.0 \\, \\text{nM} \\left( 1 + 2.000 \\right)$$\n$$[S] = 50.0 \\, \\text{nM} \\left( 3.000 \\right)$$\n$$[S] = 150.0 \\, \\text{nM}$$\n\nThe problem requires the answer to be rounded to three significant figures. The result of the multiplication should be reported to the least number of significant figures from the inputs, which is three (from $K_S$). The calculated value of 150.0 is therefore reported as 150.", "answer": "$$\\boxed{150}$$", "id": "2315143"}, {"introduction": "Once a signal is received, it is relayed through the cell via a transduction cascade, which can be thought of as a biological circuit. Understanding the logic of this circuit is crucial for predicting how cells will behave and how they can be controlled. This problem challenges you to analyze the well-known Ras signaling pathway, a critical regulator of cell proliferation that is often mutated in cancer [@problem_id:2315185]. By tracing the flow of information, you will determine why a gain-of-function mutation renders upstream pharmacological interventions ineffective, a core principle behind the development of targeted cancer therapies.", "problem": "A simplified model for a crucial cell proliferation pathway involves a series of proteins that transmit a signal from the cell's exterior to the nucleus. The pathway proceeds as follows: A Growth Factor (GF) binds to a Receptor Tyrosine Kinase (RTK) on the cell surface. This binding activates the RTK, which in turn recruits and activates a protein called Sos. Sos is a Guanine nucleotide Exchange Factor (GEF) that activates a small G-protein called Ras by catalyzing the exchange of its bound Guanosine Diphosphate (GDP) for Guanosine Triphosphate (GTP). GTP-bound Ras is in its 'on' state and activates a downstream kinase called B-Raf. B-Raf then initiates a kinase cascade that ultimately leads to the activation of a transcription factor, which promotes the expression of genes required for cell division. Normally, Ras has an intrinsic GTPase activity, allowing it to hydrolyze GTP back to GDP, thus turning itself 'off' and terminating the signal.\n\nConsider a specific cancer cell line that exhibits uncontrolled proliferation. Genetic sequencing reveals a mutation in the `Ras` gene. This mutation results in a Ras protein that can still bind GTP and activate B-Raf, but it is completely incapable of hydrolyzing GTP to GDP.\n\nA research team is testing four experimental drugs on this specific cancer cell line to find an effective treatment. The drugs and their mechanisms are as follows:\n- Drug W: A competitive inhibitor that binds to the active site of the RTK, preventing the Growth Factor from binding.\n- Drug X: An allosteric inhibitor that prevents Sos from interacting with Ras.\n- Drug Y: An inhibitor that specifically blocks the kinase activity of B-Raf.\n- Drug Z: A molecule that prevents the final transcription factor from binding to its target DNA sequences.\n\nAssuming each drug is 100% effective at its designated task, which of the following drugs would be successful in halting the uncontrolled proliferation of this particular cancer cell line?\n\nA. Drug Y only\n\nB. Drugs W and X\n\nC. Drugs Y and Z\n\nD. Drugs W, X, and Y\n\nE. All four drugs would be successful.", "solution": "The pathway can be represented as a linear signal flow:\n$$\\text{GF} \\to \\text{RTK} \\to \\text{Sos (GEF)} \\to \\text{Ras-GTP} \\to \\text{B-Raf} \\to \\text{kinase cascade} \\to \\text{TF} \\to \\text{gene expression} \\to \\text{proliferation}.$$\nRas cycles between inactive GDP-bound and active GTP-bound forms through:\n$$\\text{Ras-GDP} \\xrightarrow{\\text{Sos}} \\text{Ras-GTP}, \\quad \\text{Ras-GTP} \\xrightarrow{\\text{intrinsic GTPase}} \\text{Ras-GDP}.$$\nIn the described cancer cell line, the Ras mutant retains GTP binding and B-Raf activation but lacks all GTPase activity. Therefore, once in the GTP-bound state, Ras cannot return to the GDP-bound state. This removes the off-reaction, so:\n$$\\text{Ras-GTP} \\not\\to \\text{Ras-GDP}.$$\nConsequently, any Ras that is GTP-loaded remains persistently active, driving B-Raf and the downstream cascade independently of ongoing upstream input.\n\nEvaluate each drug under the assumption of perfect effectiveness at its specific target:\n1. Drug W (RTK competitive inhibitor): This blocks GF binding and RTK activation, but the constitutively active Ras-GTP does not require upstream RTK signaling to remain active. Therefore, blocking RTK does not stop signaling from Ras-GTP onward. Drug W is not sufficient to halt proliferation.\n2. Drug X (blocks Sos-Ras interaction): This prevents the conversion $\\text{Ras-GDP} \\to \\text{Ras-GTP}$. However, because the mutant cannot hydrolyze GTP, any existing $\\text{Ras-GTP}$ persists indefinitely, sustaining B-Raf activation and the downstream cascade. Thus, preventing further loading does not extinguish the already active Ras pool. Drug X is not sufficient to halt proliferation.\n3. Drug Y (B-Raf kinase inhibitor): This directly blocks the immediate effector of Ras. Even with constitutively active Ras-GTP, B-Raf activity is inhibited, stopping propagation through the kinase cascade. Drug Y is sufficient to halt proliferation.\n4. Drug Z (blocks the final transcription factor from binding DNA): This interrupts the last required step for expression of division genes, regardless of upstream activation states. Drug Z is sufficient to halt proliferation.\n\nHence, only drugs acting at or downstream of B-Raf will succeed here. Both Drug Y and Drug Z are successful; inhibitors of RTK or Sos are not.", "answer": "$$\\boxed{C}$$", "id": "2315185"}, {"introduction": "Cells rarely respond to signals in isolation; they integrate information from their environment and their own internal state to produce a finely tuned response. This practice delves into this concept of signal integration, examining how a cell's metabolic condition—sensed through the intracellular NADH/NAD$^+$ ratio—can modulate a survival pathway [@problem_id:2315182]. You will use kinetic and allosteric principles, including the Hill equation, to quantify how changes in cellular metabolism can alter the steady-state output of a signaling cascade, revealing the sophisticated logic that governs cellular decision-making.", "problem": "In cellular response to low oxygen levels (hypoxia), the metabolic state of the cell shifts, leading to an increase in the intracellular ratio of NADH/NAD$^+$. This change can directly influence signaling pathways. Consider a simplified model of one such pathway involving a pro-survival kinase, SAK, and a protein phosphatase, MSP2.\n\nSAK is activated by phosphorylation, and we can assume its phosphorylation occurs at a rate proportional to the concentration of unphosphorylated SAK, governed by a pseudo-first-order rate constant $k_{phos}$. The active, phosphorylated form of SAK (pSAK) is inactivated by dephosphorylation, a reaction catalyzed by the phosphatase MSP2. The dephosphorylation rate is proportional to the concentration of pSAK. The rate constant for this dephosphorylation is directly proportional to the activity of MSP2.\n\nThe activity of MSP2 is allosterically inhibited by Nicotinamide Adenine Dinucleotide (NADH). The fractional activity of MSP2, denoted $A_{MSP2}$, which ranges from 0 (fully inhibited) to 1 (fully active), is described by the following equation:\n$$A_{MSP2} = \\frac{1}{1 + \\left(\\frac{[NADH]}{K_I}\\right)^n}$$\nwhere $[NADH]$ is the intracellular NADH concentration, $K_I$ is the inhibition constant, and $n$ is the Hill coefficient that describes the cooperativity of the inhibition. The overall dephosphorylation rate constant is thus given by $k_{dephos,max} \\cdot A_{MSP2}$, where $k_{dephos,max}$ is the maximal rate constant when MSP2 is fully active.\n\nYou are given the following parameters for this system:\n- The ratio of the maximal dephosphorylation rate constant to the phosphorylation rate constant is $\\frac{k_{dephos,max}}{k_{phos}} = 20$.\n- The inhibition constant for NADH binding to MSP2 is $K_I = 150 \\, \\mu M$.\n- The Hill coefficient for the inhibition is $n = 2$.\n- Under normal oxygen conditions (normoxia), the steady-state intracellular NADH concentration is $[NADH]_{norm} = 50 \\, \\mu M$.\n- Under hypoxic conditions, the steady-state concentration rises to $[NADH]_{hyp} = 450 \\, \\mu M$.\n\nAssuming the total concentration of SAK in the cell remains constant between normoxic and hypoxic states, calculate the ratio of the steady-state concentration of phosphorylated SAK under hypoxic conditions to that under normoxic conditions, i.e., $\\frac{[pSAK]_{hyp}}{[pSAK]_{norm}}$. Report your answer as a number rounded to three significant figures.", "solution": "Let $[S]$ denote unphosphorylated SAK and $[p] \\equiv [\\text{pSAK}]$. Phosphorylation is first order in $[S]$ with rate $k_{phos}[S]$, and dephosphorylation is first order in $[p]$ with rate $k_{dephos}([NADH])[p]$, where\n$$\nk_{dephos}([NADH]) = k_{dephos,max}\\,A_{MSP2}([NADH]),\\quad A_{MSP2}([NADH])=\\frac{1}{1+\\left(\\frac{[NADH]}{K_{I}}\\right)^{n}}.\n$$\nAt steady state, phosphorylation equals dephosphorylation:\n$$\nk_{phos}[S] = k_{dephos}([NADH])[p].\n$$\nWith $[S_{tot}] = [S]+[p]$ constant, the steady-state fraction of phosphorylated SAK is\n$$\nf \\equiv \\frac{[p]}{[S_{tot}]} = \\frac{k_{phos}}{k_{phos}+k_{dephos}([NADH])} = \\frac{1}{1+\\frac{k_{dephos,max}}{k_{phos}}A_{MSP2}([NADH])}.\n$$\nDefine $r \\equiv \\frac{k_{dephos,max}}{k_{phos}}$. Then\n$$\nf([NADH]) = \\frac{1}{1+r\\,A_{MSP2}([NADH])}.\n$$\nHence the desired ratio is\n$$\nR \\equiv \\frac{[p]_{hyp}}{[p]_{norm}} = \\frac{f([NADH]_{hyp})}{f([NADH]_{norm})} = \\frac{1+r\\,A_{MSP2}([NADH]_{norm})}{1+r\\,A_{MSP2}([NADH]_{hyp})}.\n$$\nCompute $A_{MSP2}$ in each condition using $K_{I}$ and $n=2$:\n$$\nA_{MSP2}([NADH]_{norm}) = \\frac{1}{1+\\left(\\frac{50}{150}\\right)^{2}} = \\frac{1}{1+\\frac{1}{9}} = \\frac{9}{10},\n$$\n$$\nA_{MSP2}([NADH]_{hyp}) = \\frac{1}{1+\\left(\\frac{450}{150}\\right)^{2}} = \\frac{1}{1+9} = \\frac{1}{10}.\n$$\nGiven $r=\\frac{k_{dephos,max}}{k_{phos}}=20$, substitute into $R$:\n$$\nR = \\frac{1+20\\cdot\\frac{9}{10}}{1+20\\cdot\\frac{1}{10}} = \\frac{1+18}{1+2} = \\frac{19}{3} = 6.333\\ldots\n$$\nRounded to three significant figures, $R=6.33$.", "answer": "$$\\boxed{6.33}$$", "id": "2315182"}]}